Magenta Therapeutics Inc

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 2015 and is headquartered in Cambridge, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at a price to the public of $8.00 per share. The total

Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

The company announced the pricing of a public offering of common stock.

Why Shares of Magenta Therapeutics Are Plunging Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.00 per share. Magenta also granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its common stock. The gross proceed

Magenta Therapeutics Announces Pricing of Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of $60 million of its common stock. Magenta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of

Magenta Therapeutics Launches Proposed Public Offering

NEW YORK, June 15, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Investors who purchased Magenta securities are encouraged...

MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Magenta Therapeutics, Inc. and Encourages Investors to Contact the Firm

As of late, it has definitely been a great time to be an investor in Magenta Therapeutics.

Magenta Therapeutics' Shares March Higher, Can It Continue?

argenx

bluebird bio

Blueprint Medicines

Epizyme

Fate Therapeutics

The American Society of Hematology (ASH) hosted its 61st annual meeting, and one of the biggest biotech events, earlier this week in Orlando, Florida.

Wedbush’s Top Picks After ASH Annual Meeting

Molecular Templates

New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.

2 Small-Cap Biotechs That Soared Last Week

Magenta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

News for Magenta Therapeutics Inc Stock (MGTA)